Small Molecule Inhibitor Shows Promise In Trastuzumab-resistant Metastatic Breast Cancer

Researchers report that a combination of trastuzumab and neratinib a novel small molecule inhibitor of the HER2 receptor appears active in women with HER2-positive metastatic breast cancer who have progressed on previous trastuzumab based therapies. More than one-quarter of the women in a phase I/II trial had their tumors shrink on the combination therapy.

Read the whole article on Science Daily

More from Science Daily